-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $95

Benzinga·12/17/2025 15:02:32
Listen to the news
RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target from $82 to $95.